CONTROVERSIES IN NEUROLOGY SECTION EDITOR: VLADIMIR HACHINSKI, MD, FRCPC, DSCMED Do They Prevent the Progression of the Disease? George Rice, MD, FRCPC; George Ebers, MD, FRCPC HERE IS little doubt score on the Kurtzke Expanded Dis- duction by presenting the attack fre- that treatment of ability Status Scale) compared with quency in patients followed up for multiple sclerosis 28% of patients treated with pla- 102 weeks. This percentage de- (MS) with type 1 in- cebo. This difference did not reach rived from a post hoc subgroup T terferons reduces the statistical significance (P = .16). analysis that was not corrected for frequency of clinical exacerba- Several reasons were offered to the statistically challenging effect of tions. This observation has been cor- explain this shortfall in disability multiple comparison. Further- roborated repeatedly. Treatment of outcome. First, the study was nei- more, much of the effect can be at- 124 patients with recombinant in- ther designed nor powered statisti- tributed to an unusually high fre- terferon beta-1b (IFN-b-1b) re- cally to identify a moderate effect on quency of attacks that occurred in duced the frequency of attacks by disease progression. This would have small numbers of patients in the pla- 33.8%.
JAMA Neurology – American Medical Association
Published: Dec 1, 1998